Literature DB >> 28964747

Safety and efficacy of early feeding based on clinical assessment at 4 hours after ERCP: a prospective randomized controlled trial.

Chan Hyuk Park1, Jang Han Jung2, Bomi Hyun2, Hye Ji Kan2, Jin Lee2, Sea Hyub Kae2, Hyun Joo Jang2, Dong Hee Koh2, Min Ho Choi2, Moon Jae Chung3, Seungmin Bang3, Se Woo Park2.   

Abstract

BACKGROUND AND AIMS: The optimal timing of refeeding after ERCP is unknown. Some practices keep the patient fasting for 24 hours after ERCP, whereas others resume feeding earlier. We aimed to evaluate the risk of post-ERCP pancreatitis (PEP) in patients who initiate early feeding, based on their clinical assessment, including serum amylase testing performed at 4 hours after ERCP.
METHODS: Patients who were scheduled for ERCP were recruited. Patients without abdominal pain and tenderness and a serum amylase level within 1.5-fold the upper limit of normal at 4 hours after ERCP were randomly assigned to either the 4-hour fasting or 24-hour fasting group. Patients from the 4-hour fasting group started oral intake 4 hours after ERCP, whereas those from the 24-hour fasting group fasted for 24 hours after ERCP.
RESULTS: Among the 276 enrolled, PEP was identified in 3 (2.2%) from the 4-hour fasting group and in 5 (3.6%) from the 24-hour fasting group, with a rate difference of -1.4% (1-sided 97.5% confidence interval, -∞ to 2.5%). Four-hour fasting was non-inferior to 24-hour fasting in terms of PEP incidence. The total medical costs for treatment-related ERCP were significantly lower in the 4-hour fasting group than in the 24-hour fasting group (1157.20 ± 311.90 vs 1311.20 ± 410.70 U.S. dollars; P = .032).
CONCLUSION: Early feeding in patients without abdominal pain and tenderness and a serum amylase level <1.5-fold the upper limit of normal at 4 hours after ERCP does not increase the incidence of PEP after ERCP and decreases medical costs. (Clinical trial registration number: KCT0002354.).
Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28964747     DOI: 10.1016/j.gie.2017.09.021

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  3 in total

Review 1.  Endoscopic Retrograde Cholangiopancreatography-Related Complications and Their Management Strategies: A "Scoping" Literature Review.

Authors:  Kemmian D Johnson; Abhilash Perisetti; Benjamin Tharian; Ragesh Thandassery; Priya Jamidar; Hemant Goyal; Sumant Inamdar
Journal:  Dig Dis Sci       Date:  2019-12-02       Impact factor: 3.199

2.  Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study.

Authors:  Rongrong Wang; Weili Wang; Kuifen Ma; Xin Duan; Fangfang Wang; Mingzhu Huang; Wei Zhang; Tingbo Liang
Journal:  Front Pharmacol       Date:  2020-08-19       Impact factor: 5.810

3.  The prognostic value of serum and urine amylase levels and blood count parameters in assessing the risk of post-endoscopic pancreatitis development.

Authors:  Andrzej Jamry
Journal:  Prz Gastroenterol       Date:  2021-06-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.